Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma By Ogkologos - February 24, 2026 348 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Factors Associated with COVID-19 Severity Among Patients with Cancer March 22, 2021 Age: the forgotten cancer risk factor? May 29, 2023 How Genomic Testing Brought Me a Sense of Control During Metastatic... April 6, 2021 Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο January 25, 2020 Load more HOT NEWS El cáncer en mi comunidad: Cómo superar las desigualdades en la... Terminally Ill ‘Flamingo Lady’ Gets Emotional After Dying Wish Comes True Nivolumab and Ipilimumab Effective against Melanoma That Has Spread to the... Presence of Tumour and Higher Levels of LAG3-positive T-cells in the...
